What is ImmunoScape?
ImmunoScape operates at the intersection of bioinformatics and immunology, providing a sophisticated technology platform designed for the high-resolution characterization of human immune responses. The company's core offering, the Deep Immunomics platform, integrates mass cytometry, single-cell sequencing, and proprietary computational tools to deliver actionable insights into immune system dynamics. By enabling researchers and clinicians to visualize and analyze immune data with unprecedented clarity, ImmunoScape is establishing itself as a critical infrastructure provider for the next generation of immunotherapy and vaccine development. Its market position is defined by its ability to bridge the gap between raw biological data and clinical decision-making, serving as a vital partner for pharmaceutical and biotech entities focused on immune-mediated diseases.
How much funding has ImmunoScape raised?
ImmunoScape has raised a total of $39M across 3 funding rounds:
Unspecified
$11M
Unspecified
$14M
Other Financing Round
$14M
Unspecified (2020): $11M with participation from Anzu Partners, Utec, and NPR Holdings
Unspecified (2021): $14M led by Anzu Partners LLC, University of Tokyo Edge Capital Partners, and EDBI
Other Financing Round (2022): $14M supported by EDBI and Anzu Partners
Key Investors in ImmunoScape
EDBI
EDBI is a global investor based in Singapore, focusing on high-growth technology sectors since 1991. The company aims to create value and empower businesses to build sustainable legacies through strategic investments.
Anzu Partners
Anzu Partners is an investment firm focused on breakthrough technologies in clean tech, industrial, and life sciences sectors, managing $1 billion in assets.
UTEC
UTEC is a venture capital firm approved by the University of Tokyo, focusing on investing in startups that leverage exceptional intellectual property and talent to contribute to society.
What's next for ImmunoScape?
With the recent strategic investment, ImmunoScape is well-positioned to scale its operational capacity and expand its footprint in the global life sciences market. The company is expected to prioritize the enhancement of its computational bioinformatics suite, ensuring that its data analysis tools remain at the cutting edge of the industry. Furthermore, the firm will likely focus on deepening its strategic partnerships with academic institutions and global pharmaceutical leaders to accelerate the adoption of its immunomics platform in clinical trials. As the demand for precision medicine continues to rise, ImmunoScape's ability to provide high-fidelity immune profiling will be instrumental in driving the development of more effective, personalized therapeutic interventions, ultimately solidifying its role as a cornerstone of modern immunomics research.
See full ImmunoScape company page
